Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

by Zacks Equity Research

Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

    Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

    by Zacks Equity Research

    Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

      AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

      by Zacks Equity Research

      AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).

        Arpita Dutt headshot

        Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

        by Arpita Dutt

        While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

          Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat

          by Zacks Equity Research

          Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.

            Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib

            by Zacks Equity Research

            Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.

              Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View

              by Zacks Equity Research

              Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.

                Mylan (MYL) Beats on Q1 Earnings, Revenues Miss Estimates

                by Zacks Equity Research

                Mylan's (MYL) first-quarter results beat on earnings but missed the top line due to a decline in EpiPen sales.

                  Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View

                  by Zacks Equity Research

                  Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.

                    Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1

                    by Zacks Equity Research

                    Epizyme, Inc. (EPZM) reported a loss of 56 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of loss of 63 cents but wider than the year-ago loss of 41 cents.

                      The Zacks Analyst Blog Highlights: Arcelor Mittal, Roche Holding AG and Cummins

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Arcelor Mittal, Roche Holding AG and Cummins

                        Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death

                        by Zacks Equity Research

                        Kite Pharma, Inc. (KITE) reported wider-than-expected loss in the first quarter of 2017.

                          John Blank headshot

                          The European Union Got Stronger: Global Week Ahead

                          by John Blank

                          This Global Week Ahead started with a foregone conclusion: Emmanuel Macron is the new French president. Imagine the sighs of relief. However, it was a 'sell the news' trading event.

                            What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

                            by Zacks Equity Research

                            Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

                              Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss

                              by Zacks Equity Research

                              Ophthotech Corporation (OPHT) reported first-quarter 2017 loss of $1.20 per share, narrower than the Zacks Consensus Estimate of a loss of $1.31 but wider than the year-ago loss of $1.03

                                Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start

                                by Zacks Equity Research

                                Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share.

                                  What to Expect from Epizyme (EPZM) This Earnings Season?

                                  by Zacks Equity Research

                                  Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell.

                                    Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus

                                    by Zacks Equity Research

                                    Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.

                                      What to Expect from Prothena (PRTA) This Earnings Season?

                                      by Zacks Equity Research

                                      Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.

                                        Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales

                                        by Zacks Equity Research

                                        Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

                                          by Arpita Dutt

                                          Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

                                            Ryan McQueeney headshot

                                            After Johnson & Johnson Earnings, Buy These Pharma Stocks

                                            by Ryan McQueeney

                                            Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.

                                              Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion

                                              by Zacks Equity Research

                                              Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).

                                                Roche's Hemophilia A Drug Positive in Second Phase III Study

                                                by Zacks Equity Research

                                                Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.

                                                  Roche Launches Antibody Test to Diagnose Prostate Cancer

                                                  by Zacks Equity Research

                                                  Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.